(Q44648884)

5 December 2017

title

Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate: two-year substudy results (English)

1 reference

medroxyprogesterone acetate

5 December 2017

1 reference

1 reference

Leon Speroff

5

1 reference

5 December 2017

James H. Pickar

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14607581

30 March 2024

I. Tien Yeh

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14607581

30 March 2024

James E. Wheeler

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14607581

30 March 2024

Mary F. Cunnane

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14607581

30 March 2024

language of work or name

English

0 references

publication date

1 November 2003

1 reference

full work available at URL

5 December 2017

http://www.fertstert.org/article/S0015028203011671/pdf

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14607581

https://api.elsevier.com/content/article/PII:S0015028203011671?httpAccept=text/xml

30 March 2024

1 reference

https://api.crossref.org/works/10.1016/S0015-0282(03)01167-1

https://api.elsevier.com/content/article/PII:S0015028203011671?httpAccept=text/plain

30 March 2024

1 reference

https://api.crossref.org/works/10.1016/S0015-0282(03)01167-1

30 March 2024

published in

Fertility and Sterility

1 reference

5 December 2017

volume

80

1 reference

5 December 2017

issue

5

1 reference

5 December 2017

page(s)

1234-1240

1 reference

Low-dose esterified estrogen therapy: effects on bone, plasma estradiol concentrations, endometrium, and lipid levels. Estratab/Osteoporosis Study Group

5 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2901167-1

Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2901167-1

Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2901167-1

Low-dosage micronized 17 beta-estradiol prevents bone loss in postmenopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2901167-1

Personal perspective on low-dosage estrogen therapy for postmenopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2901167-1

Risk of endometrial cancer in relation to use of low-dose, unopposed estrogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2901167-1

Low-potency oestrogen and risk of endometrial cancer: a case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2901167-1

Hormone replacement therapy and endometrial cancer risk: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2901167-1

Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2901167-1

Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2901167-1

Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Estrogen/Progestin Interventions Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2901167-1

Effects of hormone replacement therapy on the endometrium and lipid parameters: a review of randomized clinical trials, 1985 to 1995.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2901167-1

Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. The Menopause Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2901167-1

Endometrial safety of hormone replacement therapy: review of literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2901167-1

Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2901167-1

Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2901167-1

A multicentric European study testing the reproducibility of the WHO classification of endometrial hyperplasia with a proposal of a simplified working classification for biopsy and curettage specimens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2901167-1

Reproducibility of the diagnosis of endometrial hyperplasia, atypical hyperplasia, and well-differentiated carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2901167-1

Agreement in assessing endometrial pathology: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2901167-1

The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2901167-1

Psychosocial factors associated with the use of hormonal replacement therapy in a longitudinal follow-up of Swedish women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2901167-1

Determinants of long-term hormone replacement therapy and reasons for early discontinuation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2901167-1

Risk factors associated with women's compliance with estrogen replacement therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2901167-1

Reduced mortality associated with long-term postmenopausal estrogen therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2901167-1

Postmenopausal unopposed estrogens. Characteristics of use in relation to the risk of endometrial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2901167-1

inferred from DOI database lookup

7 January 2021

based on heuristic

Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial

12

1 reference

https://api.crossref.org/works/10.1016/S0015-0282(03)01167-1

The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART study). A randomized controlled trial.

30 March 2024

14

1 reference

https://api.crossref.org/works/10.1016/S0015-0282(03)01167-1

30 March 2024

Identifiers

1 reference

5 December 2017

1 reference